Ligand Pharmaceuticals Incorporated
LGND
$104.27
$2.982.94%
| Weiss Ratings | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D+ | |||
| Rating Factors | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.38 | |||
| Price History | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.10% | |||
| 30-Day Total Return | -14.69% | |||
| 60-Day Total Return | -5.45% | |||
| 90-Day Total Return | -14.16% | |||
| Year to Date Total Return | -3.83% | |||
| 1-Year Total Return | 28.05% | |||
| 2-Year Total Return | 39.05% | |||
| 3-Year Total Return | 52.61% | |||
| 5-Year Total Return | 79.52% | |||
| 52-Week High % Change | -22.02% | |||
| 52-Week Low % Change | 49.57% | |||
| Price | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $129.90 | |||
| 52-Week Low Price | $67.72 | |||
| 52-Week Low Price (Date) | Apr 22, 2024 | |||
| 52-Week High Price (Date) | Nov 07, 2024 | |||
| Valuation | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.95B | |||
| Enterprise Value | 1.70B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.16 | |||
| Earnings Per Share Growth | -105.55% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 11.50 | |||
| Price/Book (Q) | 2.33 | |||
| Enterprise Value/Revenue (TTM) | 10.18 | |||
| Price | $104.27 | |||
| Enterprise Value/EBITDA (TTM) | 29.20 | |||
| Enterprise Value/EBIT | 73.90 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 18.97M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 550 7500 | |||
| Address | 555 Heritage Drive Jupiter, FL 33458 | |||
| Website | www.ligand.com | |||
| Country | United States | |||
| Year Founded | 1987 | |||
| Profitability | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 13.77% | |||
| Profit Margin | -2.41% | |||
| Management Effectiveness | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.66% | |||
| Return on Equity | -- | |||
| Income Statement | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 167.13M | |||
| Total Revenue (TTM) | 167.13M | |||
| Revenue Per Share | $8.81 | |||
| Gross Profit (TTM) | 134.63M | |||
| EBITDA (TTM) | 58.26M | |||
| EBIT (TTM) | 23.02M | |||
| Net Income (TTM) | -4.03M | |||
| Net Income Avl. to Common (TTM) | -4.03M | |||
| Total Revenue Growth (Q YOY) | 52.35% | |||
| Earnings Growth (Q YOY) | -270.93% | |||
| EPS Diluted (TTM) | -0.16 | |||
| EPS Diluted Growth (Q YOY) | -259.09% | |||
| Balance Sheet | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 256.17M | |||
| Cash Per Share (Q) | $13.50 | |||
| Total Current Assets (Q) | 331.56M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 830.44M | |||
| Current Ratio (Q) | 8.934 | |||
| Book Value Per Share (Q) | $43.46 | |||
| Total Assets (Q) | 941.77M | |||
| Total Current Liabilities (Q) | 37.11M | |||
| Total Debt (Q) | 7.15M | |||
| Total Liabilities (Q) | 111.34M | |||
| Total Common Equity (Q) | 830.44M | |||
| Cash Flow | LGND - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -143.66M | |||
| Cash from Financing (TTM) | 97.14M | |||
| Net Change in Cash (TTM) | 49.35M | |||
| Levered Free Cash Flow (TTM) | 100.79M | |||
| Cash from Operations (TTM) | 97.05M | |||
